Epithalon
Research OnlyAlso known as: Epitalon, Epithalone, AGAG, AEDG peptide
A synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson, claimed to activate telomerase and extend lifespan. 2025 independent Western research confirmed telomerase activation in vitro. Still not approved anywhere; no controlled human clinical trials.
Research Statistics
Russian-origin bioregulator; telomerase activation confirmed in vitro but no controlled human RCTs.
Research Dossier
Overview
What is Epithalon and what does the research say?
Mechanism of Action
The proposed mechanisms of Epithalon are based primarily on Russian research with recent independent in vitro validation in 2025. Human mechanistic data from controlled trials is lacking.
How It Works (Simplified)
Epithalon targets cellular aging through telomere maintenance and related pathways:
Upregulates hTERT gene transcription, leading to increased telomerase enzyme production that maintains and extends telomere length.
Interacts with histone proteins to decondense heterochromatin, potentially reactivating genes that become silenced with age.
Stimulates pineal gland function and melatonin synthesis, which typically decline with age, affecting sleep and circadian rhythms.
Increases activity of protective enzymes like SOD and glutathione peroxidase, reducing oxidative damage to cells and DNA.
Scientific Pathways
Telomerase Activation Pathway (Cellular Longevity)
Epithalon → Epigenetic Modulation → hTERT Gene Transcription ↑
↓
Telomerase Reverse Transcriptase (TERT) ↑
↓
Telomerase Enzyme Assembly → Telomere ElongationChromatin Remodeling Pathway (Gene Expression)
Epithalon → Histone Interactions (H1, H2b, H3, H4) → Heterochromatin Decondensation
↓
Reactivation of Age-Silenced GenesKey Research: Ullah et al. (UK, 2025) provided first independent Western confirmation of telomerase activation and telomere elongation in human fibroblasts. PMC12411320
Important Limitations
- ~95% of research from single institute (St. Petersburg Institute of Bioregulation and Gerontology)
- 2025 independent replication confirms in vitro effects only - no human clinical validation
- Translation from cell culture to whole-body anti-aging effects is unconfirmed
- ALT (alternative lengthening of telomeres) pathway activation in cancer cells raises safety questions
- Pharmacokinetics, optimal dosing, and bioavailability in humans not characterized
- No controlled human clinical trials have demonstrated any anti-aging benefits
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on preclinical data: Initial effects on gene expression may begin. In vitro studies show hTERT upregulation within days of treatment. Melatonin effects in animal models observed early in treatment.
Continued treatment in cell culture shows progressive telomere effects. Chromatin remodeling and epigenetic changes may develop. Pineal function restoration observed in animal models within weeks.
Extended cellular replicative capacity observed in fibroblast cultures. Animal studies typically used treatment periods of several weeks. Antioxidant enzyme upregulation reported.
Long-term effects are based on animal lifespan studies. Russian protocols often involve cyclical treatment (10-20 days on, rest periods). Human pharmacokinetics and optimal duration are unknown.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Epithalon product quality
Good Signs (7 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Epithalon with other peptides. Based on published research and mechanistic considerations.
Thymosin-Alpha-1
CompatibleBoth developed within Russian peptide bioregulation research - epithalon for telomerase activation, Ta1 for immune modulation. No known direct interactions.
GHK-Cu
CompatibleDifferent anti-aging mechanisms may be complementary - GHK-Cu modulates gene expression for tissue repair, epithalon targets telomere maintenance.
Selank
CompatibleBoth Russian bioregulator peptides with distinct targets - epithalon for pineal/longevity, Selank for anxiolytic effects via GABA modulation.
Semax
CompatibleBoth Russian nootropic-class peptides - Semax provides acute neuroprotection via BDNF, epithalon targets longer-term telomere effects.
BPC-157
CompatibleDifferent regenerative targets - BPC-157 for tissue healing, epithalon for cellular longevity. No known contraindications in combination.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Epithalon
Epithalon Calculators
Related Peptides
Endoluten
Pineal cytamin, Pineal gland peptides, A-8 pineal peptides
A cytamin-class peptide supplement derived from pineal gland tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for pineal function and melatonin support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
FOXO4-DRI
FOXO4-D-Retro-Inverso, FOXO4-DRI Peptide, Proxofim
A D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction, selectively eliminating senescent cells (senolytic). Preclinical studies in aged mice demonstrated restored fitness, fur density, and renal function. No human clinical trials conducted. More selective than BCL-2 inhibitors but remains unproven in humans.
Glutathione
GSH, L-Glutathione, Reduced Glutathione +1 more
The master antioxidant and most abundant intracellular thiol in mammalian cells. This naturally occurring tripeptide (glutamate-cysteine-glycine) is essential for detoxification, immune function, and cellular protection. Extensively studied with strong mechanistic understanding and growing clinical evidence.
Humanin
HN, HNG, S14G-Humanin +2 more
A 24-amino acid mitochondria-derived peptide (MDP) discovered in 2001 that shows cytoprotective, anti-apoptotic, and neuroprotective effects in preclinical studies. Represents a novel class of signaling molecules encoded within mitochondrial DNA. Extensive academic research with emerging interest in aging, metabolic disease, and neurodegeneration, but no approved clinical applications.
MOTS-c
Mitochondrial ORF of the 12S rRNA type-c, Mitochondrial-derived peptide, MOTS-C peptide
A 16-amino acid mitochondrial-derived peptide encoded in mtDNA that targets AMPK/mTOR pathways for metabolic regulation. Preclinical studies show exercise mimetic and geroprotective effects. Lower MOTS-c levels found in T2D patients. No clinical trials yet conducted in humans.
SHLP-2
Small Humanin-Like Peptide 2, SHLP2, Mitochondrial-Derived Peptide 2
A 26-amino acid mitochondria-derived peptide (MDP) discovered in 2016 from the same mitochondrial DNA region as humanin. Shows cytoprotective, metabolic, and potential longevity effects in preclinical studies. Part of an emerging class of mitochondrial signaling molecules, but human therapeutic data is lacking.
Related Content
Thymalin
Immune · moderate evidence
Cortexin
Cognitive · moderate evidence
Vilon
Immune · low evidence
What is Epithalon?
An introduction to epithalon, a synthetic tetrapeptide studi...
Bronchogen vs Epithalon
View side-by-side analysis
Cardiogen vs Epithalon
View side-by-side analysis